durvalumab phase 1/2, trial summary

A randomised clinical trial investigating the effect of durvalumab versus nil in patients with locally-advanced or metastatic urothelial carcinoma of the bladder who had progressed while on or after a platinum-containing chemotherapy, including those who progressed within 12 months of receiving therapy in a neoadjuvant or adjuvant setting

Studied treatment	durvalumab at 10 mg/kg body weight administered as an intravenous infusion over 60 minutes every two weeks until disease progression or unacceptable toxicity
Control treatment

Patients	patients with locally-advanced or metastatic urothelial carcinoma of the bladder who had progressed while on or after a platinum-containing chemotherapy, including those who progressed within 12 months of receiving therapy in a neoadjuvant or adjuvant setting
Group sizes	-9 / -9

Blindness	Inclusion period
Follow-up duration	Centers
Lost to FU	geographical localisation
Primary endpoint	Design	Single-arm study

phase 1/2

Links

press release

Registering number	(see trial on clinicaltrials.gov)
Code Name	Study 1108